Inhaled Product & Device Technology, GlaxoSmithKline, Hertfordshire, UK.
AAPS PharmSciTech. 2012 Sep;13(3):978-89. doi: 10.1208/s12249-012-9822-3. Epub 2012 Jul 14.
The purpose of this article is to review the suitability of the analytical and statistical techniques that have thus far been developed to assess the dissolution behavior of particles in the respirable aerodynamic size range, as generated by orally inhaled products (OIPs) such as metered-dose inhalers and dry powder inhalers. The review encompasses all analytical techniques publicized to date, namely, those using paddle-over-disk USP 2 dissolution apparatus, flow-through cell dissolution apparatus, and diffusion cell apparatus. The available techniques may have research value for both industry and academia, especially when developing modified-release formulations. The choice of a method should be guided by the question(s) that the research strives to answer, as well as by the strengths and weaknesses of the available techniques. There is still insufficient knowledge, however, for translating the dissolution data into statements about quality, performance, safety, or efficacy of OIPs in general. Any attempts to standardize a dissolution method for compendial inclusion or compendial use would therefore be premature. This review reinforces and expands on the 2008 stimulus article of the USP Inhalation Ad Hoc Advisory Panel, which "could not find compelling evidence suggesting that such dissolution testing is kinetically and/or clinically crucial for currently approved inhalation drug products."
本文旨在回顾迄今为止开发的用于评估口服吸入产品(如定量吸入器和干粉吸入器)所产生的可吸入空气动力学粒径范围内颗粒的溶出行为的分析和统计技术的适用性。本综述涵盖了迄今为止公布的所有分析技术,即使用桨叶过盘 USP2 溶出仪、流通池溶出仪和扩散池仪的技术。现有的技术可能对工业界和学术界都具有研究价值,尤其是在开发控释制剂时。方法的选择应根据研究旨在回答的问题以及现有技术的优缺点来指导。然而,对于将溶出数据转化为关于口服吸入产品的质量、性能、安全性或疗效的陈述,目前的知识还不够充分。因此,任何试图为收录或使用药典标准化溶出方法的尝试都将是不成熟的。本综述加强和扩展了 USP 吸入特遣咨询小组在 2008 年的刺激性文章,该文章“没有发现令人信服的证据表明,这种溶出测试对于目前批准的吸入药物产品在动力学和/或临床方面是至关重要的”。